Literature DB >> 8558536

Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase.

P F Jackson1, D C Cole, B S Slusher, S L Stetz, L E Ross, B A Donzanti, D A Trainor.   

Abstract

A series of substituted phosphonate derivatives were designed and synthesized in order to study the ability of these compounds to inhibit the neuropeptidase N-acetylated alpha-linked acidic dipeptidase (NAALADase). The molecules were shown to act as inhibitors of the enzyme, with the most potent (compound 3) having a Ki of 0.275 nM. The potency of this compound is more than 1000 times greater than that of previously reported inhibitors of the enzyme. NAALADase is responsible for the catabolism of the abundant neuropeptide N-acetyl-aspartylglutamate (NAAG) into N-acetylaspartate and glutamate. NAAG has been proposed to be a neurotransmitter at a subpopulation of glutamate receptors; alternatively, NAAG has been suggested to act as a storage form of synaptic glutamate. As a result, inhibition of NAALADase may show utility as a therapeutic intervention in diseases in which altered levels of glutamate are thought to be involved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558536     DOI: 10.1021/jm950801q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  69 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

4.  Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.

Authors:  Vincent Bouvet; Melinda Wuest; Justin J Bailey; Cody Bergman; Nancy Janzen; John F Valliant; Frank Wuest
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

5.  2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.

Authors:  Morris H Baslow; Victor V Dyakin; Karen L Nowak; Basalingappa L Hungund; David N Guilfoyle
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  Design and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.

Authors:  Pingyu Ding; Paul Helquist; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2007-11-17       Impact factor: 3.641

7.  Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Authors:  Abhijit A Date; Rana Rais; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Ajit G Thomas; Sarah C Zimmermann; Alexandra J Gadiano; Gilad Halpert; Barbara S Slusher; Laura M Ensign
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

8.  Prostate specific membrane antigen (PSMA) imaging: the past is prologue.

Authors:  Peter L Choyke; Kirsten Bouchelouche
Journal:  Transl Androl Urol       Date:  2019-08

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

10.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.